Back to top
more

Ligand Pharmaceuticals (LGND)

(Delayed Data from NSDQ)

$115.45 USD

115.45
135,153

-6.63 (-5.43%)

Updated Nov 14, 2024 04:00 PM ET

After-Market: $115.48 +0.03 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Arena's (ARNA) Etrasimod Meets Phase II Colitis Study Goal

by Zacks Equity Research

Arena's (ARNA) ulcerative colitis candidate, etrasimod leads to clinical remission in 33% of the patients.

    Geron (GERN) Q4 Loss Flat Y/Y, Revenues Surge, Shares Up

    by Zacks Equity Research

    Geron (GERN) misses earnings and sales estimates in Q4. However, revenues almost double year over year. Imetelstat remains in focus.

      Agenus (AGEN) Q4 Loss Wider Than Expected, Revenues Miss

      by Zacks Equity Research

      Agenus (AGEN) posts wider-than-expected loss and misses on revenue estimate in the fourth quarter of 2017.

        Alexion (ALXN) Gains On Positive Date From Lead Candidate

        by Zacks Equity Research

        Alexion's (ALXN) shares gained 3.4% following positive results from a phase III study on its important candidate, ALXN1210, wherein it was compared to its lead drug Soliris.

          Catalyst (CPRX) Posts In-Line Q4 Loss, Pipeline in Progress

          by Zacks Equity Research

          Catalyst Pharma (CPRX) reports in-line fourth-quarter 2017 loss and is on track to resubmit its new drug application for Firdapse in the first quarter of 2018.

            Arena Pharmaceuticals (ARNA) Q4 Earnings Beat, Sales Down Y/Y

            by Zacks Equity Research

            Arena (ARNA) reports narrower-than-expected Q4 loss. However, revenues decrease year over year. The company is likely to advance ralinepag in phase III study in the second half of 2018.

              Solid Biosciences (SLDB) Hit by Clinical Hold on Lead Drug

              by Zacks Equity Research

              Shares of Solid Biosciences (SLDB) were hit after the FDA put a clinical hold on a phase III study of lead DMD candidate, SGT-001.

                Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q4

                by Zacks Equity Research

                Epizyme (EPZM) reports narrower-than-expected loss in the fourth quarter of 2017.

                  AbbVie's Uterine Fibroids Candidate Succeeds in Phase III

                  by Zacks Equity Research

                  AbbVie (ABBV) and partner Neurocrine Biosciences announce that the second of the two pivotal phase III studies evaluating elagolix, met the primary endpoint for treating women with uterine fibroids.

                    Sarepta to Seek Rapid Approval for Second DMD Drug, Stock Up

                    by Zacks Equity Research

                    Sarepta (SRPT) will file a rolling NDA for its second DMD drug, golodirsen. The submission is expected to be completed in late 2018.

                      Biogen to Buy Mid-Stage Neuropsychiatry Asset From Pfizer

                      by Zacks Equity Research

                      Biogen (BIIB) agrees to pay $75 million upfront to buy mid-stage candidate from Pfizer, which is being developed for cognitive impairment associated with schizophrenia (CIAS).

                        Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4

                        by Zacks Equity Research

                        Merrimack (MACK) reports narrower-than-expected loss in the fourth quarter due to lower operating expenses.

                          Aradigm Files MAA for Bronchiectasis Candidate in the EU

                          by Zacks Equity Research

                          Aradigm (ARDM) submits regulatory applications for its bronchiectasis candidate, Linhaliq, in the EU. A response from the EMA is awaited within 21 days to notify if the filing is complete.

                            Regeneron and Sanofi Announce Positive Data on Praluent

                            by Zacks Equity Research

                            Regeneron (REGN) & Sanofi's Praluent achieves the primary endpoint in the ODYSSEY OUTCOMES trial as the drug reduces the overall risk of MACE by 15%.

                              Pfizer Gets FDA Panel Backing for New Indication for Xeljanz

                              by Zacks Equity Research

                              Pfizer's (PFE) Xeljanz received a unanimous vote from an FDA advisory committee to include the ulcerative colitis (UC) indication in its label .

                                Corcept Plans Korlym Label Expansion, Pipeline in Progress

                                by Zacks Equity Research

                                Corcept (CORT) is currently working on developing Korlym for additional indications. It also remains focused at the development of its pipeline progress.

                                  Bayer, BASF in Talks for Vegetable Seeds Business Sell-Off

                                  by Zacks Equity Research

                                  Bayer (BAYRY) is in exclusive talks with BASF for the divestiture of its entire vegetable seeds business.

                                    Celldex (CLDX) Q4 Loss Narrows, Revenues Beat, Shares Up

                                    by Zacks Equity Research

                                    Celldex (CLDX) reports narrower-than-expected loss in Q4 with sales also beating estimates. Moreover, shares rise in after-hours trading on Mar 7 following the results.

                                      Conatus (CNAT) Loss Narrower Than Expected in Q4, Sales Miss

                                      by Zacks Equity Research

                                      Conatus (CNAT) reports narrower-than-expected loss in Q4 while revenues marginally fall short of estimates. However, the top line shows a massive year-over-year increase.

                                        Bristol-Myers' Opdivo gets FDA Nod for Every Four Week Dosing

                                        by Zacks Equity Research

                                        Bristol-Myers (BMY) Opdivo becomes the first and only FDA-approved PD-1 inhibitor for every four-week dosing.

                                          Lilly, Boehringer to Expand Jardiance Heart Failure Program

                                          by Zacks Equity Research

                                          Lilly (LLY) and Boehringer plan to expand their clinical trial program for Jardiance in chronic heart failure through clinical trials.

                                            Spectrum (SPPI) Q4 Loss Widens Y/Y, Sales Miss, Stock Falls

                                            by Zacks Equity Research

                                            Spectrum (SPPI) reports narrower-than-expected loss in the fourth quarter, while it misses on revenues. Rolontis successful in phase III study.

                                              Dermira's Acne Candidate Fails in Pivotal Trials, Shares Sink

                                              by Zacks Equity Research

                                              Dermira's (DERM) pipeline candidate, olumacostat glasaretil, fails to meet primary endpoints in two pivotal studies, which evaluate its efficacy for treating moderate-to-severe acne vulgaris.

                                                FDA Accepts Regeneron/Sanofi's Dupixent sBLA for Asthma

                                                by Zacks Equity Research

                                                Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi announced that the FDA has accepted the companies' sBLA for Dupixent for asthma with a target date of Oct 20, 2018.

                                                  Aduro (ADRO) Q4 Loss Narrower Than Expected, Revenues Miss

                                                  by Zacks Equity Research

                                                  Aduro (ADRO) reports narrower-than-expected loss in Q4. However, sales miss estimates and fall year over year on declining grant revenues.